Royalty Pharma plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.5B+12.0% YoYTTM through 30 Jun 2026
Net Income $812M-5.5% YoYTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 59.8% |
| Operating Margin | 89.3% |
| Net Margin | 32.0% |
Returns
8.3%ROE
4.1%ROA
4.5%ROIC
Balance Sheet Health
Debt / Equity0.92x
Current Ratio2.80x
Net Debt$8.1B
Cash & Equivalents$812M
Quality Metrics
Altman Z-Score2.64
Piotroski F-Score6 / 9
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $2.4B
Diluted EPS$1.86TTMFY2025: $1.78
Dividend
$0.47Per share, FY20260.80%Yield-7.1%5-yr growth
Capital Allocation
R&D Spend$238.6M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Royalty Receipts | $887M | +13.0% | View detailsExpected to continue growing as newly acquired royalties scale up. |
| Portfolio Receipts | $925M | +10.0% | View detailsFull year 2026 guidance raised to between $3,325 million and $3,450 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.